Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
5 studies found for:    15273990 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers
Condition: Neoplasms
Interventions: Drug: AZD 2281;   Drug: Cisplatin;   Drug: Gemcitabine
2 Completed ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer
Conditions: Neoplasms;   Lymphoma
Interventions: Drug: ABT-888;   Drug: Cyclophosphamide
3 Withdrawn ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems
Condition: Neoplasms
Interventions: Drug: ABT-888;   Drug: Carboplatin;   Drug: Paclitaxel
4 Recruiting Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
Conditions: Advanced Ovarian Cancer;   Primary Peritoneal Cancer;   Advanced Breast Cancer;   Advanced Solid Tumors
Intervention: Drug: BMN 673
5 Completed Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas
Conditions: Solid Tumors;   Lymphomas
Interventions: Drug: ABT-888;   Drug: Topotecan

Indicates status has not been verified in more than two years